A meta-analysis encompassing six pivotal SGLT2-inhibitor trials, EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, CREDENCE, VERTIS CV, and SCORED, demonstrated a significant reduction in the time to the first event of major adverse cardiovascular events (MACEs), encompassing CV death, myocardial infarction (MI), and stroke, across diverse HF clinical stages [35]. The gene discussed is SLC5A2; the disease is myocardial infarction.